TOP STORIES

• BUSINESS Novartis Overhauls Sales Model to Prioritize Solving Regional Treatment Gaps
  November 14, 2025

• REGULATORY Nipro-Samsung Alliance Nears First Approval in Japan with Stelara Biosimilar
  November 14, 2025

• REGULATORY Japan Panel to Review KalVista’s Oral HAE Drug, GSK’s Asthma Med, and More on Nov. 27
  November 14, 2025

• BUSINESS Keytruda Again Tops Japan Market in July-September: IQVIA
  November 14, 2025

• BUSINESS Bayer, Regeneron Move to Block Fuji’s Newly Listed Eylea Biosimilar in Japan
  November 13, 2025

• REGULATORY LDP Study Group Seeks Uniform 5% Drug Price Hike, Warns of US MFN Spillover
  November 12, 2025

• BUSINESS J&J Japan Targets Top Share in Key Disease Areas by 2030: New President
  November 12, 2025

• REGULATORY Japan’s 1st Biosimilars for Eylea, Actemra Get NHI Listing in November
  November 11, 2025

• REGULATORY MOF Pushes Stronger Use of CEA for Pricy Meds towards FY2026 Budget
  November 11, 2025

• REGULATORY Growth Strategy Council Seeks Stronger Drug Discovery Infrastructure in Economic Plan
  November 11, 2025

• COMMENTARY Japan’s Trading Houses Gain Ground in Pharma, Rewriting the Industry Playbook
  November 10, 2025

• BUSINESS MSD Japan Chief Voices Regret over Delay in Routine HPV Shots for Males
  November 10, 2025

• REGULATORY MHLW Weighs Higher Copay Ratios for LLPs; 1/2 to Full Gap on the Table
  November 7, 2025

• BUSINESS Novo Nordisk Taps Keisuke Kotani as New Japan Chief
  November 7, 2025

• REGULATORY Keytruda Faces 5th Price Cut under Special Re-Pricing; MSD Warns of Ripple Effects
  November 6, 2025

• REGULATORY MOF Floats New Patient Cost Scheme, Eyes Revival of Old Copay System
  November 6, 2025

• REGULATORY Japan Launches Growth Strategy HQ, Sets Drug Discovery as Priority Field
  November 5, 2025

• BUSINESS Fuji, J&J Reach Agreement on Simponi Biosimilar for 2026 Debut
  November 5, 2025

• BUSINESS Sumitomo within Striking Distance of 250-Billion-Yen Goal for 3 Key Drugs
  November 4, 2025

• BUSINESS Daiichi Sankyo’s Profit Down on HER3-DXd Delay, One-Off CMO Costs
  November 4, 2025

ページ

• « 先頭
• ‹ Prev
• …
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• …
• Next ›
• 最終 »